

# DLL3

Catalog # PVGS1830

## Product Information

---

<b>Primary Accession Species</b>	<a href="#">Q9NYJ7-1</a> Human
<b>Sequence</b>	Val311-Ala479
<b>Purity</b>	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
<b>Endotoxin Level</b>	Less than 1EU per $\mu$ g by the LAL method.
<b>Biological Activity</b>	Immobilized DLL3 Domain (311-479), His&Avi, Human (Cat.No.: Z03951) at 1 $\mu$ g/ml (100 $\mu$ l/Well) on the plate can bind Anti-DLL3 Antibody, hFc Tag
<b>Expression System</b>	HEK293
<b>Theoretical Molecular Weight</b>	21.20 kDa
<b>Formulation Reconstitution</b>	Lyophilized from a 0.22 $\mu$ m filtered solution in PBS, (pH 7.4). It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH <sub>2</sub> O more than 100 $\mu$ g/ml.
<b>Storage &amp; Stability</b>	Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

## Additional Information

---

<b>Target Background</b>	Delta-like ligand 3 (DLL3) is an inhibitory Notch ligand. It is highly expressed on the surface of Small cell lung cancer (SCLC) and other neuroendocrine tumors. And its expression promotes SCLC migration and invasion. DLL3 agents are evaluated in several ongoing clinical studies in SCLC and other neuroendocrine tumors.
--------------------------	---

## Protein Information

---

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.